Who is sponsoring NCT05304572?

NCT05304572 is sponsored by Assiut University.

What drugs are being tested in NCT05304572?

Interventions in NCT05304572: Multi-Detector CT angiography, Trans-arterial chemoembolization and DSA.

What condition does NCT05304572 study?

NCT05304572 studies Hepatocellular Carcinoma.

Is NCT05304572 still recruiting?

NCT05304572 is currently completed. Last updated 15 June 2023.

Last reviewed 2023-06-15 · How we verify

NCT05304572

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multi-Detector CT Angiography With 3D Reconstruction Versus Digital Subtraction Angiography

Completed Last updated 15 June 2023

What this trial tests

trial testing Multi-Detector CT angiography in Hepatocellular Carcinoma in 70 participants. Completed in 1 June 2023.

Timeline

1 May 2022

Primary endpoint
1 May 2023

1 June 2023

Quick facts

Lead sponsor	Assiut University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	70
Start date	1 May 2022
Primary completion	1 May 2023
Estimated completion	1 June 2023
Sites	1 location across Egypt

Drugs / interventions tested

Multi-Detector CT angiography
Trans-arterial chemoembolization and DSA

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →

Sponsor

Assiut University

Who can join

Eligibility, any sex, with Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to investigate the feasibility and accuracy of Multi-Detector CT angiography acquired before Trans-arterial Chemo-embolization (TACE) in detecting Hepato-cellular carcinoma feeding vessels compared to DSA angiography acquired during TACE.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Detection of hepatocellular carcinoma feeding vessels: MDCT angiography with 3D reconstruction versus digital subtraction angiography.
Ahmed RM, Ali WA, AbdelHakam AM, Ahmed SH. · · 2024 · cited 2× · PMID 39294600 · DOI 10.1186/s12880-024-01408-z
Detection of hepatocellular carcinoma feeding vessels: MDCT angiography with 3D reconstruction versus digital subtraction angiography
Ahmed RM, Ali WA, AbdelHakam AM, Ahmed SH. · · 2024 · DOI 10.21203/rs.3.rs-4566334/v1

Verify or expand the search:

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05304572 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 15 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05304572.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing